63529-31-7

Upstream product

• 369-32-4 1-(4-fluoro-3-methylphenyl)ethanone 

Downstream Products

• 78864-10-5 [5-(4-fluoro-3-methyl-phenyl)-thiazol-2-yl]-(2-methoxy-phenyl)-amine 
• 78312-05-7 1-(4-Fluoro-3-methyl-phenyl)-2-(7-fluoro-2H-[1,2,4]triazino[5,6-b]indol-3-ylsulfanyl)-ethanone 
• 78312-09-1 1-(4-Fluoro-3-methyl-phenyl)-2-(8-fluoro-2H-[1,2,4]triazino[5,6-b]indol-3-ylsulfanyl)-ethanone 
• 339001-12-6 C₁₈H₂₂FNO 
• 78864-09-2 (4-ethoxy-phenyl)-[5-(4-fluoro-3-methyl-phenyl)-thiazol-2-yl]-amine 
• 1443769-90-1 2-(1-ethyl-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl)-1-(4-pyrimidin-2-ylpiperazin-1-yl)ethanone 
• 1443770-08-8 (1-ethyl-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl)acetonitrile 
• 1443770-07-7 2-benzyloxymethyl-1-ethyl-4-(4-fluoro-3-methylphenyl)-1H-imidazole 
• 1443770-06-6 2-benzyloxy-N-ethyl-N-[2-(4-fluoro-3-methylphenyl)-2-oxo-ethyl]acetamide 
• 1443770-05-5 2-ethylamino-1-(4-fluoro-3-methylphenyl)ethanone hydrochloride 
• 1443770-09-9 (1-ethyl-4-(4-fluoro-3-methylphenyl)-1H-imidazol-2-yl)acetic acid 
• 1268088-45-4 C₁₁H₁₄FNO 
• 1443142-87-7 2-(4-(4-fluoro-3-methyl-phenyl)-2-phenyl-imidazol-1-yl)-1-(2-methyl-4,5,7,8-tetrahydro-thiazolo[4,5-d]azepin-6-yl)-ethanone 
• 1239982-53-6 2-(4-bromophenylamino)-4-(4-fluoro-3-methylphenyl)thiazole 

Relevant academic research and scientific papers

Identification of a novel selective small-molecule inhibitor of protein arginine methyltransferase 5 (PRMT5) by virtual screening, resynthesis and biological evaluations

As one of the most promising anticancer target in protein arginine methyltransferase (PRMT) family, PRMT5 has been drawing more and more attentions, and many efforts have been devoted to develop its inhibitors. In this study, three PRMT5 inhibitors (9, 16

SUBSTITUTED DIHYDROPYRAZOLO PYRAZINE CARBOXAMIDE DERIVATIVES

The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

MACROCYCLIC INDOLE DERIVATIVES

The present invention relates to macrocyclic indole derivatives of general formula (I) : (I), in which R1, R2, R3, R4, R5, R6, A and L are as defined herein, methods of preparing said compounds, intermediate compounds useful for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds, and the use of said compounds for manufacturing pharmaceutical compositions for the treatment or prophylaxis of diseases, in particular of hyperproliferative disorders, as a sole agent or in combination with other active ingredients.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3, R3a have meanings given in the description.

4-ARYL IMIDAZOLE DERIVATIVES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, Ar, R1, R2, R3, R3a have meanings given in the description.

PIPERAZINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLU5 RECEPTORS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurologic

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurologic

3-O-Substituted benzyl pyridazinone derivatives as COX inhibitors

New 3-O-substituted benzyl pyridazinone compounds have been synthesised and evaluated for their cyclooxygenase inhibitory activity and COX-2 selectivity. Among the compounds synthesised, three compounds (11b-11d) have shown in vitro COX-2 selectivity. These compounds have been evaluated for their in vivo potential using carrageenan-induced rat paw edema assay. One compound (11b) showed 32% anti-inflammatory activity at 30 mg kg-1 dose.